A
Alcista
Alcista · 25%CSTL
$18.34
Precio del escenario
$33.190
-1.138 (-3.43%)Al cierre
Loading chart…
- Máximo
- 34.550
- Apertura
- 34.130
- Precio medio ponderado por volumen
- 33.60
- Volumen
- 335.42K
- Capitalización
- 584.17M
- Mínimo
- 33.060
- Importe
- 11.27M
- EV/EBITDA, TTM
- 302.82
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Análisis de IA of Castle Biosciences Inc (CSTL)
MantenerCastle Biosciences Inc (CSTL) is currently not a strong buy due to its low RSI of 32.804 indicating oversold conditions, but it has a positive revenue growth outlook with Q2 2026 revenue reported at $103.5 million, a 20% increase year-over-year. The main risk is its negative net income of $2.1 million in Q2 2026, which raises concerns about profitability.
Métricas de valoración
El PER previsto actual de Castle Biosciences Inc (CSTL) es 0.00, frente a su media de 5 años de -12.59.
Escenarios de precio de Alphio AI para CSTL
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CSTL en cartera
Cronología de eventos
Noticias
9.510-15PRnewswireCastle Biosciences to Release Q3 Financial Results on Nov. 5, 2026
5.010-12PRnewswireCastle Biosciences Unveils New TissueCypher Data at ACG 2026
8.509-30PRnewswireCastle Biosciences Presents New DecisionDx-Melanoma Data at EADV Congress
8.509-30NewsfilterCastle Biosciences Presents New Data on DecisionDx-Melanoma at EADV 2026
8.509-28NASDAQ.COMCastle Biosciences Publishes Study on TissueCypher Test Impact
Preguntas frecuentes sobre CSTL, respondidas por Alphio AI
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC). It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Castle Biosciences Inc (CSTL) is currently not a strong buy due to its low RSI of 32.804 indicating oversold conditions, but it has a positive revenue growth outlook with Q2 2026 revenue reported at $103.5 million, a 20% increase year-over-year. The main risk is its negative net income of $2.1 million in Q2 2026, which raises concerns about profitability.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.